	US 12,433,956 B2
	Method of administering a nanoparticle
Daniel Gonzalez Carter, Kanagawa (JP); and Kazunori Kataoka, Kanagawa (JP)
Assigned to KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION, Kawasaki (JP)
Appl. No. 17/907,029
Filed by KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION, Kawasaki (JP)
PCT Filed Mar. 19, 2021, PCT No. PCT/JP2021/011290 § 371(c)(1), (2) Date Sep. 22, 2022, PCT Pub. No. WO2021/193393, PCT Pub. Date Sep. 30, 2021.
Claims priority of application No. 2020-055478 (JP), filed on Mar. 26, 2020.
Prior Publication US 2023/0145172 A1, May 11, 2023
Int. Cl. A61K 47/69 (2017.01); A61K 47/68 (2017.01)

CPC A61K 47/6907 (2017.08) [A61K 47/6849 (2017.08); A61K 47/6898 (2017.08)]

9 Claims

1. A method of administering a nanoparticle to a subject, comprising:

administering to the subject an effective amount of an antibody that binds to an antigen expressed on a surface of a brain endothelial cell such that a sufficient amount of the antibody can bind to the surface of the brain endothelial cell, wherein the antibody is conjugated to a 1^stmolecule; and

administering to the subject a nanoparticle that is coated with a 2^ndmolecule that binds to the 1^stmolecule under a physiological condition in a brain blood vessel such that the nanoparticle can bind to the 1^stmolecule that has attached to the surface of the brain endothelial cell,

wherein the nanoparticle is administered after a completion of the administration of the antibody.